The result indicated that administration of erythropoietin in patients suffering from kidney failure particularly through the venous route increases the incidence of red blood cell aplasia, however, this increase was not statistically significant and this condition may occur due to any of the two methods venous or subcutaneous injection. The gene discussed is EPO; the disease is kidney failure.